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The sentinel lymph node biopsy (SLNB) represents a minimal invasive surgical method for axillary staging in patients with primary
breast cancer. In a prospective study, evaluation of quality of life (QOL) and arm morbidity was performed before surgery on a total
of 56 breast cancer patients. The EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires were used for QOL assessment.
Assessment of pain was additionally observed using the McGill Pain Questionnaire. Arm mobility was observed by goniometric
measurement of arm movement. Data were collected before surgery (t1), 1 week after discharge (t2) and 9–12 months after
surgery (t3).
The type of axillary surgery does not seem to affect global QOL at a short-time follow-up, but patients recover sooner after SLNB.
Body image and sexual functioning remain stable in both types of axillary surgery. Arm/shoulder pain was reported in 36% of patients
after SLNB in comparison to 68% receiving axillary lymph node dissection (ALND), and ‘numbness’ was reported only in 4% of
patients in the SLNB group vs 19.3% after ALND. Abduction, flexion and horizontal adduction of the affected arm show significant
impairment after ALND. Breast cancer patients should be counselled about the benefits of SLNB over ALND concerning QOL and
postsurgery side effects in a short-term follow-up.
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Axillary lymph node dissection (ALND) in breast cancer patients
still represents the routine surgical method for axillary staging.
Although the axillary node status is the most important prognostic
factor for recurrence and survival (Fisher et al, 1984; Carter et al,
1989) and information obtained by axillary dissection is useful for
planning adjuvant treatment, it is associated with substantial
morbidity (Kissin et al, 1986; Ivens et al, 1992; Keramopoulos et al,
1993; Hack et al, 1999; Kakuda et al, 1999) and psychological
distress (Maunsell et al, 1993; Tobin et al, 1993; Shimozuma et al,
1999). Hack et al, showed arm/shoulder pain, weakness or
numbness in 72% and impaired range of motion in 73% of breast
cancer patients after ALND, whereas high levels of quality of life
(QOL) were reported. Moderate to severe pain was reported
between 20, 23 and 32% (Van Dam et al, 1993; Kuehn et al, 2000;
Ververs et al, 2001) and was not significantly related to time since
surgery. Other reports suggest that arm problems after ALND are
associated with a negative effect on the overall QOL of breast
cancer patients (Maunsell et al, 1993; Kuehn et al, 2000). As a
result of the need to reduce axillary morbidity, many investigations
have been performed on sentinel lymph node biopsy (SLNB), an
alternative procedure. Using vital dye and/or radiocolloid, the
sentinel node/s as the first lymph node to receive lymphatic
drainage from the primary tumour can be identified by a minimal
invasive surgical technique. Recently, published data showed no
sensory morbidity after SLNB (Giuliano et al, 2000) at a median
follow-up of 39 months. Schrenk et al (2000) reported less
postoperative arm pain, numbness and arm motion restriction
after SLNB at a follow-up period of 15.4 months. The evaluation of
morbidity after ALND vs SLNB is under investigation in ongoing
randomised trials as the NSABP B-32 and the ALMANAC trial. The
evaluation of QOL issues such as treatment side effects, patients
satisfaction and symptom management are substantial parameters
in decision making regarding surgical interventions. However, at
this time little is known about the impact of SLNB on QOL in
breast cancer patients.
The major objectives of this study are (1) to evaluate QOL
differences in a short-term follow-up after two surgical procedures
(ALND and SLNB) in breast cancer patients receiving breast-
conserving treatment; (2) to determine the impact of SLNB on
global QOL of breast cancer patients and (3) to compare morbidity
end points (arm/shoulder mobility, pain, sensory morbidity)
during different clinical phases.
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lMATERIALS AND METHODS
Selection of patients
In a prospective, longitudinal study between September 2000 and
March 2002, we included 56 consecutive patients with newly
diagnosed primary breast cancer. Study eligibility criteria included
the following: (1) breast cancer stage I or II, (2) breast-conserving
surgery in all patients, (3) patients’ age between 18 and 80 years,
(4) no severe physical and mental comorbidity, (5) performance
status 0 and (6) informed consent.
Procedures
A total of 56 patients with invasive breast cancer received the
sentinel node biopsy. In all, 25 patients receiving the SLNB only
(Group I) were compared with 31 patients who underwent the
standard level I and II ALND (Group II) when intraoperative
frozen section showed metastatic disease. Before the study was
started, a surgical protocol was implemented in order to minimise
differences in technique. Similar incisions, similar anatomic
dissections and similar drainage catheters were used. All patients
received breast-conserving surgery. Our technique of SLNB has
been described previously (Reitsamer et al, 2002). Briefly, SLNB
was performed by the combined method using peritumoral
injection of technetium-99m-labelled albumin (Nanocoll
s, Sorin
Biomedica, Saluggia, Italy) and subareolar subcutaneous injection
of blue dye (Patent Blue V
s, Laboratoire Guerbet, Aulnay-sous-
Bois, France). Technetium-99m was injected 16–18h before
surgery and blue dye was injected 5min prior to incision to
identify the SLN. Hot and blue nodes were removed and frozen
section was performed immediately. If SLN/s were negative in
frozen section, patients had no further ALND. All patients received
whole-breast irradiation after surgery. No radiotherapy to the
axilla was performed. Adjuvant chemotherapy was administered
before radiotherapy when indicated. Adjuvant endocrine treatment
was initiated after surgery. The decision to use adjuvant
chemotherapy or hormone therapy was mainly based on
prognostic factors from the primary breast tumour such as
tumour size, hormone receptor status and/or HER-2/neu status.
Additionally, node-positive patients received adjuvant hormone
therapy by participating in the national hormone treatment trial.
Assessments
Frequency Data were collected at three time points: before
surgery (t1), 1 week after discharge (t2), and 9–12 months after
surgery (t3).
EORTC QLQ-C30 The European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire QLQ-C30,
version 3.0, a cancer-specific questionnaire, is composed of five
functional scales (physical, role, emotional, cognitive, social), the
global health status and nine symptom scales (fatigue, nausea and
vomiting, pain, dyspnoea, insomnia, appetite loss, constipation,
diarrhoea, financial difficulties). The global health status correlates
significantly with all the functional and symptom scales (Aaronson
et al, 1993). For the functional and global QOL scales a higher
score indicates a better level of functioning. All patients answered
this questionnaire before surgery (t1), 1 week after discharge (t2)
and 9–12 (t3) months after surgery.
EORTC QLQ-BR23 The European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire QLQ-BR23, the
breast cancer module, incorporates four symptom scales (systemic
therapy side effects, breast symptoms, arm symptoms, upset by
hair loss) and four functional scales (body image, sexual
functioning, sexual enjoyment, future perspective). All scores
obtained from scales and single items range from 0 to 100. A
higher score indicates a better level of functioning. All patients
answered this questionnaire before surgery (t1), and 9–12 months
after surgery (t3).
Range of arm/shoulder motion All patients underwent gonio-
metric measurement of the affected arm by a physiotherapist at
every time point. Measurements of the following arm movements
were obtained: shoulder flexion, shoulder extension, shoulder
abduction, horizontal abduction and horizontal adduction.
McGill Pain Questionnaire German version (Melzack, 1975; Stein
and Mendl, 1988). This questionnaire is composed of sensory,
affective, evaluative word descriptors in the form of 78 words
grouped into 20 subclasses used by patients to specify subjective
pain experience and of a visual analogue pain scale for
measurement of pain intensity. The questionnaire provides
information about the site of pain and the relative effects of a
given manipulation on several dimensions of pain. All patients
completed the questionnaire at every time point.
Karnofsky performance status scale (KPS) The KPS scale consists
of 11 components describing patients’ mobility and ability to
maintain employment, live at home and care for oneself. The
scores used by clinicians range from 0 (worst physical condition)
to 100 (best physical status).
Statistical analysis
Statistical methodology was used in accordance with The EORTC
QLQ-C30 Scoring Manual (Fayers et al, 1999). In order to compare
both types of surgery (ALND vs SLNB) nonparametric indepen-
dent two-sided tests were applied (Wald–Wolfowitz test, Kolmo-
gorov–Smirnov test, Mann–Whitney U-test) to all variables
tested. Differences of the proportions of patients reporting pain
after ALND over time were analysed using the Cochran’s Q test.
The same test was applied for analysis of the SLNB group. A P-
value less than 5% was considered as significant.
RESULTS
In all, 56 breast cancer patients participated in this study. Patients’
clinical and demographic characteristics are summarized in
Table 1. The mean number of lymph nodes dissected was 2.2 in
group I and 15.0 in group II. The percentage of postmenopausal
patients was 71.4%. Preoperative arm symptoms, the Karnofsky
performance status and QOL levels were comparable between both
groups. Table 2 provides QOL levels (EORTC QLQ-C30) at all time
points of assessment. The mean scores at baseline assessment (t1)
showed that patients’ global QOL and emotional functioning were
more affected in both groups than physical functioning, role
functioning, cognitive functioning and social functioning. How-
ever, significant improvement of global QOL (P¼0.002) occurs at
t2 only in patients after SLNB (Figure 1). Analysis of means of
symptom scales shows significant higher levels of pain at t2 in
patients after ALND (P¼0.03) (Figure 2). Comparison of QOL
dimensions assessed by the EORTC QLQ-C30 and QLQ-BR23
(Tables 2 and 3) shows no statistically significant differences
among patients in both groups before surgery (t1). At t3, global
QOL improved in both groups, but there were no statistically
significant differences in any dimension of QOL. Karnofsky
performance scores at baseline were high in both groups and
showed no significant changes over time (Table 3).
Analysis of arm/shoulder mobility assessment data showed
significant impairment of abduction and flexion in the operated
arm at the time points t2, t3 and of horizontal adduction at the
time point t3 in group II (Table 4).
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lAnalysis of data assessed by the McGill Pain Questionnaire
showed significantly more sensory problems of the affected arm in
group II at t3 when the number of words chosen (NWC) was
compared with those of group I. Severity of pain measured by the
visual analogue scale showed that women in group II reported
significantly greater pain than in group I at t3 (Table 5).
Arm/shoulder pain was reported in only 36% of patients after
SLNB in comparison to 68% after ALND at t2. While the number of
patients with pain decreased significantly over time in the ALND
group at t3 (Cochran’s Q, P¼0.008), no significant changes could
be found in the SLNB group (P¼0.08). Arm symptoms assessment
by the EORTC QLQ-BR23 questionnaire showed no significant
difference in both the groups at t3 (Table 3).
DISCUSSION
The present study confirms previous observations suggesting that
SLNB is associated with less arm/shoulder morbidity (Giuliano
et al, 2000; Schrenk et al, 2000; Burak et al, 2002; Haid et al, 2002;
Temple et al, 2002) than ALND. Evaluation and comparison of
QOL outcomes in a short time follow-up in breast cancer patients
undergoing ALND or SLNB after breast-conserving surgery
provides additional observations:
(1) The type of axillary surgery does not seem to have an impact
on global QOL, but may affect other QOL aspects as pain. (2) Body
image and sexual functioning remain stable during the postsurgery
follow-up in both types of axillary surgery. (3) The SLNB is
associated with mild pain and mild sensory morbidity, signifi-
cantly less than ALND, improving during the months following
surgery. (4) Arm/shoulder abduction, flexion and horizontal
Table 1 Patient characteristics
Total sample
(n¼56)
ALND
(n¼31)
SLNB
(n¼25) P-value
Age (years)
Mean 60.1 57.7 61.4 0.27
Site of axillary surgery (%)
Right axilla 51.7 54.8 48.0 0.62
Left axilla 48.3 45.2 52.0 0.6
Cancer type (%)
Invasive ductal 62.5 64.5 56.0 0.52
Invasive lobular 14.3 6.5 24.0 0.07
Invasive ductal and intraductal 23.2 29.0 20.0 0.44
Tumour size (%)
pT1 71.4 74.2 68.0 0.62
pT2 28.6 25.8 32.0 0.62
Adjuvant treatment (%)
HT and RT 67.9 67.7 68.0 0.62
CT and RT 23.2 29.0 20.0 0.44
RT alone 8.9 3.3 12.0 0.22
Menopausal status (%)
Premenopausal 28.6 35.5 20.0 0.20
Postmenopausal 71.4 64.4 80.0 0.20
Civil status (%)
Married/partnership 53.6 58.1 48.0 0.45
Single/widowed/divorced 30.4 35.5 24.0 0.36
Unknown 16.0 6.4 28.0 0.03
Education (%)
Primary 44.6 51.6 40.0 0.39
Secondary/professional 25.0 25.8 24.0 0.86
Higher 14.3 16.1 12.0 0.66
Unknown 16.1 6.5 24.0 0.06
HT¼hormone therapy; RT¼radiotherapy; CT¼chemotherapy.
Table 2 Means (s.d.) of the EORTC QLQ-C30 scale scores
ALND SLNB P-value
Before surgery (t1)
Global QOL 63.8 (24.9) 55.9 (25.9) 0.87
Physical functioning 87.7 (19.2) 90.8 (17.9) 0.69
Role functioning 88.0 (26.1) 90.9 (17.7) 0.69
Emotional functioning 65.3 (21.6) 53.8 (31.1) 0.05
Cognitive functioning 80.6 (21.9) 84.0 (23.8) 0.41
Social functioning 85.9 (23.6) 84.8 (22.3) 0.75
Pain 14.1 (23.2) 18.7 (27.0) 0.90
After discharge (t2)
Global QOL 57.8 (20.5) 68.5 (17.0) 0.58
Physical functioning 82.3 (15.4) 86.7 (14.9) 0.37
Role functioning 60.2 (28.0) 70.4 (30.9) 0.37
Emotional functioning 75.6 (21.3) 70.7 (27.3) 0.07
Cognitive functioning 86.1 (22.3) 90.7 (14.7) 0.65
Social functioning 78.7 (28.4) 83.4 (22.0) 0.65
Pain 34.3 (29.2) 16.7 (20.4) o0.05
a
9–12 months after surgery (t3)
Global QOL 72.1 (22.7) 70.2 (20.3) 0.45
Physical functioning 85.9 (21.4) 87.2 (18.2) 0.34
Role functioning 74.1 (27.6) 78.3 (26.8) 0.63
Emotional functioning 68.9 (19.8) 70.5 (25.4) 0.63
Cognitive functioning 77.6 (25.3) 82.6 (24.8) 0.21
Social functioning 86.2 (23.6) 89.8 (19.9) 0.50
Pain 21.3 (25.9) 18.8 (24.8) 0.29
aStatistically significant.
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Figure 1 Comparison of global QOL (means) after ANLD vs SLNB over
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Figure 2 Comparison of pain (means) after ALND vs SLNB over time.
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ladduction show significant impairment after ALND when com-
pared with the preoperative range of motion.
The examination of postsurgery side effects after the different
types of axillary surgery in our sample showed a significant
difference in pain severity as well as in intensity of sensory
morbidity of the affected arm after SLNB in comparison to ALND.
Numbness was reported in 19.3% of the patients after ALND in
contrast to 4% in the SLNB group, whereas ‘tugging’ was the most
common complaint in both groups. The NWC shows that even
after SLNB, a few patients experience substantial sensory
complaints of the affected arm at t3. The properties of the McGill
Pain Questionnaire in this matter are (1) exclusion of patients
reporting breast pain, (2) specification of subjective pain intensity
and (3) description of sensory qualities of pain by word
descriptors as ‘numbing’, ‘tugging’, etc. Interestingly, evaluation
of pain using the McGill Pain Questionnaire, the QLQ-C30
questionnaire and evaluation of ‘arm symptoms’ using the QLQ-
BR23 questionnaire show some discrepancy. These results support
the hypothesis, that current standard questionnaires do not cover
all aspects of QOL (Janni et al, 2001). Several aspects of morbidity
including pain, range of motion and sensory complaints of the
affected arm have been reported to show significant difference in
favour of SLNB (Giuliano et al, 2000; Schrenk et al, 2000; Burak
et al, 2002; Haid et al, 2002; Temple et al, 2002). However,
measuring instruments and scoring systems used in these studies
differ widely.
In our study, patients’ clinical and sociodemographic character-
istics regarding age, tumour stage, adjuvant treatment were well
balanced between the two groups. Using the EORTC QOL-C30
questionnaire, no significant difference could be detected in global
QOL after ALND and SLNB at a short time follow-up. Interestingly,
baseline assessment showed low levels of patients’ global QOL in
both groups increasing during follow-up. Statistically significant
higher levels of global QOL are observed at t2 and t3 after SLNB,
when compared with baseline levels. In contrast, impairment of
global QOL at t2 after ALND clearly shows a difference in QOL
improvement in favour of the SLNB group. We suggest that this is
because patients in the SLNB group recover sooner than after
ALND. However, patients having positive nodes in the ALND
group reflect a more advanced disease. Randomised trials, as the
ALMANAC trial, can possibly demonstrate the impact of axillary
status on QOL. In addition to global QOL, assessment of emotional
functioning shows low levels at baseline too, with no significant
changes during follow-up in both groups. An explanation for low
levels at baseline is that patients being informed about the breast
cancer diagnosis before surgery induced psychological distress
(Fallowfield et al, 1986; Ganz et al, 1992; Coscarelli Schag et al,
1993). In this study the Karnofsky performance status score was,
for most patients, over 90 at baseline and showed no differences in
patients’ physical condition in both groups during follow-up.
Using the EORTC QLQ-BR23 questionnaire comparison of body
image and sexual functioning showed no difference between the
two groups.
In the present study, we used a variety of validated measurement
instruments to specify reliably patients’ subjective experience of
postoperative morbidity and QOL after SLNB in comparison to
ALND. To our knowledge, this is one of the first reports to
compare various aspects of QOL and arm/shoulder morbidity after
different types of axillary surgery considering presurgery assess-
ments. However, despite the analysis of many covariates with
different measurement instruments a potential limitation of our
study may be the small sample size.
In conclusion, the SLNB as a minimal invasive technique for
axillary staging seems to be an alternative to ALND associated with
a better postsurgery arm/shoulder mobility, with less pain and less
sensory morbidity of the affected arm in a short-time follow-up.
Severity of post-treatment side effects and QOL aspects should be
considered when counselling breast cancer patients.
Table 3 Means (s.d.) of the EORTC QLQ-BR23 scale scores and
Karnofsky performance status
ALND SLNB P-value
Before surgery (t1)
Body image 89.9 (18.3) 83.2 (23.7) 0.39
Sexual functioning 30.9 (31.9) 28.7 (27.7) 0.69
Sexual enjoyment 61.5 (38.1) 52.3 (32.5) 0.95
Future perspective 38.8 (33.9) 31.8 (39.5) 0.56
Arm symptoms 8.3 (14.4) 19.5 (25.2) 0.07
KPS 98.2 (4.6) 99.1 (2.8) 0.10
9–12 months after surgery (t3)
Body image 87.9 (15.8) 92.0 (13.6) 0.45
Sexual functioning 33.4 (33.4) 35.1 (24.8) 0.45
Sexual enjoyment 63.9 (26.4) 66.7 (23.5) 0.20
Future perspective 56.7 (32.9) 54.5 (34.9) 0.18
Arm symptoms 21.2 (22.8) 14.0 (18.4) 0.26
KPS 96.1 (18.1) 99.5 (2.0) 0.21
Table 4 Means (s.d.) arm/shoulder motion, goniometric measurement
ALND SLNB P-value
Before surgery (t1)
Abduction 153.7 (19.3) 160.4 (10.9) 0.75
Flexion 152.1 (17.9) 153.6 (13.6) 0.58
Extension 50.7 (8.4) 49.3 (5.8) 0.55
Horizontal abduction 108.6 (12.8) 108.1 (12.4) 0.55
Horizontal adduction 35.1 (14.0) 32.2 (8.2) 0.98
After discharge (t2)
Abduction 128.3 (24.9) 152.3 (13.7) 0.013*
Flexion 134.8 (21.9) 150.6 (16.1) 0.04*
Extension 48.6 (11.5) 51.7 (5.0) 0.58
Horizontal abduction 106.1 (15.8) 108.4 (13.2) 0.72
Horizontal adduction 29.5 (14.4) 29.4 (11.3) 0.72
9–12 months after surgery (t3)
Abduction 143.8 (22.8) 158.9 (13.9) 0.007*
Flexion 146.0 (15.9) 154.6 (15.0) 0.03*
Extension 47.1 (11.2) 52.2 (27.1) 0.39
Horizontal abduction 101.1 (15.9) 106.5 (21.3) 0.76
Horizontal adduction 34.5 (14.1) 35.6 (19.1) 0.011*
*Po0.05.
Table 5 Means (s.d.) for pain
ALND SLNB P-value
After discharge (t2)
Sensory (NWC) 2.29 (2.67) 0.88 (1.45) 0.552
Visual analogue scale 1.45 (1.36) 0.68 (1.03) 0.823
9–12 months after surgery (t3)
Sensory (NWC) 1.45 (2.29) 0.96 (2.46) 0.026*
Visual analogue scale 1.13 (1.36) 0.68 (1.63) 0.012*
*Po0.05.
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